Both the Cystic Fibrosis Foundation and leading CF clinicians support the idea that the use of hypertonic saline is now a standard of care. The investigators believe the use of a specialized transnasal Pulmonary Aerosol Delivery (tPAD) device for administration of HS will improve on that standard of care by reducing the treatment burden during CF patients' waking hours, ensuring greater compliance and potentially improving the efficacy and tolerability of inhaled HS.